Cancer News

Engineering the Common Cold Virus Appears to be Promising Treatment Approach for Some Brain Tumors (07/06/2018)

A “smart bomb” oncolytic adenovirus appears to induce dramatic responses with long-term survival in recurrent high-grade gliomas, according to the early results of a study published in The Journal of Clinical Oncology. Glioblastoma is the most common and aggressive form of primary brain cancer in adults. With standard therapy — surgery followed by chemoradiation and …

Continue reading "Engineering the Common Cold Virus Appears to be Promising Treatment Approach for Some Brain Tumors"

Interim Survival Data from Phase 3 Trial of DCVax®-L for Glioblastoma Reported (05/30/2018)

Northwest Biotherapeutics, developer of DCVax® personalized immune therapies for solid tumor cancers, announced today the publication of interim blinded survival data from its Phase 3 clinical trial of DCVax®-L for newly diagnosed Glioblastoma brain cancer.  The data were collected by the independent contract research organization managing the trial, tabulated by an independent statistical firm and published with …

Continue reading "Interim Survival Data from Phase 3 Trial of DCVax®-L for Glioblastoma Reported"

Interim Results from Clinical Trial of Immunotherapy for Glioblastoma Show Significant Clinical Benefit (05/29/2018)

The research team behind an emerging immunotherapy for cancer will present interim findings from an ongoing clinical study in patients with brain cancer at a major research meeting next month. Collaborators from organizations including Roswell Park Comprehensive Cancer Center, the Cleveland Clinic and MimiVax LLC will share data from their phase II study of SurVaxM …

Continue reading "Interim Results from Clinical Trial of Immunotherapy for Glioblastoma Show Significant Clinical Benefit"

Pediatric MATCH Trial to Test Targeted Drugs in Childhood Cancers (08/02/2017)

Today investigators at the National Cancer Institute (NCI) and the Children’s Oncology Group (COG) announced the opening of enrollment for a unique precision medicine clinical trial. NCI-COG Pediatric Molecular Analysis for Therapy Choice (Pediatric MATCH) is a nationwide trial to explore whether targeted therapies can be effective for children and adolescents with solid tumors that …

Continue reading "Pediatric MATCH Trial to Test Targeted Drugs in Childhood Cancers"

Penn Study Suggests that Combining CAR T Cells with Existing Immunotherapies May Overcome Resistance in Glioblastomas (07/24/2017)

Donald M. O’Rourke, MD Genetically modified “hunter” T cells successfully migrated to and penetrated a deadly type of brain tumor known as glioblastoma (GBM) in a clinical trial of the new therapy, but the cells triggered an immunosuppressive tumor microenvironment and faced a complex mutational landscape that will need to be overcome to better treat …

Continue reading "Penn Study Suggests that Combining CAR T Cells with Existing Immunotherapies May Overcome Resistance in Glioblastomas"

Addition of Temodar® to Radiation in Glioma: New Standard of Care (01/19/2017)

The addition of the chemotherapy agent, Temodar® (temozolomide), to radiation therapy has demonstrated a huge survival benefit compared to treatment with radiation therapy alone among patients with newly diagnosed glioma. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology. Gliomas refer to a class of brain cancers. …

Continue reading "Addition of Temodar® to Radiation in Glioma: New Standard of Care"

Temodar® After Radiation Improves Survival in Anaplastic Gliomas (06/07/2016)

The use of the chemotherapy agent Temodar (temozolomide) following radiation therapy significantly improves time to cancer progression and overall survival among patients with newly diagnosed anaplastic glioma without 1p/19q co-deletions. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Anaplastic gliomas are a type of brain … Continue reading "Temodar® After Radiation Improves Survival in Anaplastic Gliomas"

Genetically Modified Poliovirus Granted “Breakthrough” by FDA for Glioblastoma (05/23/2016)

The United States Food and Drug Administration (FDA) has granted “breakthrough status” designation for the treatment of glioblastoma containing a genetically modified poliovirus. Glioblastoma is an extremely aggressive form of brain cancer, with few patients surviving 5 years following diagnosis. Despite efforts with surgery, chemotherapy, and/or radiation therapy, the overall outcomes for patients with glioblastoma … Continue reading "Genetically Modified Poliovirus Granted “Breakthrough” by FDA for Glioblastoma"

Avastin®/Camptosar® Improves Outcomes Compared with Temodar® in Glioblastoma (05/12/2016)

The treatment combination consisting of Avastin (bevacizumab) plus Camptosar (irinotecan) improves time to cancer progression compared to treatment with Temodar (temozolomide) in patients with newly diagnosed glioblastoma. These results were recently published in the Journal of Clinical Oncology. Glioblastoma is an extremely aggressive form of brain cancer. Standard therapy includes surgery to remove as much … Continue reading "Avastin®/Camptosar® Improves Outcomes Compared with Temodar® in Glioblastoma"

Immune Therapy for Brain Tumors: A New Promising Avenue (02/17/2016)

  Glioblastoma is a particularly aggressive type of brain cancer. Only about one fifth of adults diagnosed with it survive two years or more after their diagnosis. A new two-drug combination, currently in early clinical trials, might help people diagnosed with glioblastoma to fight the disease. In a presentation of early clinical trial data to … Continue reading "Immune Therapy for Brain Tumors: A New Promising Avenue"